Edwards Lifesciences Corporation (EW)

NYSE • Healthcare

$85.15

-$0.03 (-0.0%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$85.52

Day Range$84.89 - $86.47

Avg. Volume (3M)3.5M

Market Cap$49B

P/E Ratio48.9

52 Week Range

$72.3$96.29

Next EarningsIn 25 daysOct 29, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$1.7B100%

Gross Profitminus cost of goods$1.3B78%

Operating Incomeminus R&D and overhead$519.5M30%

Net Incomeminus taxes and the rest$241.9M14%

In plain terms: out of every $100 in revenue, Edwards Lifesciences Corporation keeps $14 as net profit.

Fundamentals & Financials

Revenue (TTM)

$6.5B

Net Income (TTM)

$1B

EPS (TTM)

$1.74

ROA (TTM)

7.25%

Current Ratio

4.52

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+7.4%Q3 2025$0.67

+12.4%Q4 2025$0.67

-6.1%Q1 2026$0.58

+7.0%Q2 2026$0.78

+5.0%Q3 2026$0.78

Oct 29

in 25 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +5.0%

Edwards Lifesciences’ revenue rose about 17% to roughly $1.7 billion in the first fiscal quarter of 2026, based on preliminary results, while net income increased about 6% to around $381 million. Operating income reached about $515 million, with gross margin near 78% and operating margin around 31%, showing profitability kept pace as the top line expanded. The company generated operating cash flow of about $43.8 million and repurchased roughly $522 million of stock.

Next report — what to expect

Edwards Lifesciences Corporation (EW) is set to report earnings on October 29, 2026. Wall Street consensus calls for EPS of $0.738 on revenue of $1.68 billion. For trailing context, revenue grew +13.6% year over year last quarter. Edwards has beaten EPS in 7 of 8 most recent quarters.

View full earnings history

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation (NYSE: EW) develops medical technology for structural heart disease, critical care, and surgical patient monitoring. The company sells to healthcare providers across the United States, Europe, Japan, and other international markets, and generated $6.1 billion of revenue in FY2025.

Name

Edwards Lifesciences Corporation

CEO

Bernard J. Zovighian

Website

www.edwards.com

Industry

Healthcare

Year Founded

1958

Employees

16,000

Today's Snapshot

AI-generated

EW closed slightly lower at 85.15, in line with a flat sector. Edwards Lifesciences won approval from the U.S. health regulator for its expandable heart valve for children.

Trading Volume

Below 10d avg (3.4M)

2.4M

vs S&P 500 Today

Underperforming Market

-0.83%

Updated: October 2, 2026 at 20:16 UTC

Technical Indicators

0 Buy2 Neutral6 Sell

EW shows downside bias with short- and medium-term averages above the current price and negative momentum and MACD underscoring selling pressure, while ADX remains low so the directional move lacks strong conviction. The 200-day average sits very close to the market, and oscillators are mixed with some signs of being oversold even as OBV registers accumulation. Volatility is moderate and the pivot is nearby, suggesting limited room for trend expansion. Technical takeaway: Strong Sell.

All signals